Clinical trial
Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study.
NCT03917303 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study.
- Lead sponsor
- Maastricht University Medical Center
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- December 23, 2019
- Completion date
- September 30, 2026
- Enrollment
- 158 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.